Advanced Search


Study ID Status Title Patient Level Data
LAMT07 Completed An open, multicentre study to evaluate the efficacy and safety of lamotrigine as add-on therapy in patients with myoclonic seizures and syndromes.
LB-01 Completed Dose Finding Study on Lamivudine in Chronic Hepatitis B Patients (Protocol LB01)
LB-02 Completed Phase III Study of Lamivudine - A Placebo-controlled, Double-blind Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-02)
LB-03 Completed Phase III Study of Lamivudine - A Long-term Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-03)
LB-04 Completed Phase III Clinical Trial of GG714 (Lamivudine): Histological Evaluation of Long-term Treatment - A Full Report of Extension Study - (Protocol No. LB-04)
LB-05 Completed Comparison of Pharmacokinetic of Lamivudine Between Elderly Volunteers and Healthy Young Male Volunteers (Protocol LB-05)
LB-06 Completed Phase III Study of Lamivudine - Follow-up Investigation after Double-blind Study (LB-02) and Long-term Study (LB-03) - (Protocol No.: LB-06)
LBI108245 Completed A multi-centre, observational study to evaluate the incidence of non-serious rash in Korean bipolar I patients with lamotrigine therapy in real world setting
LBI108614 Completed An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects Study Listed on
LBI108617 Completed An open-label, randomised, single-dose, parallel-group study to demonstrate bioequivalence of two formulations and the effect of food and water on one formulation of lamotrigine in healthy male and female volunteers Study Listed on
LBI108884 Completed An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder Study Listed on
LEP103944 Completed An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa Study Listed on
LEP105972 Completed Lamotrigine Extended-Release in Elderly Patients with Epilepsy Study Listed on
LEP108937 Completed An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects Study Listed on
LEP111102 Completed A Pivotal, Single-Dose, Randomised, Parallel-Group, Open-Label Study to Demonstrate Bioequivalence of 250mg Lamotrigine XR relative to 200mg + 50mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 250mg Lamotrigine XR in Healthy Male and Female Volunteers Study Listed on
LEX106430 Completed A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)
LP2105521 Completed A multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIa study using 18F fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on macrophage activity in subjects with atherosclerosis Study Listed on
LPL104884 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2 effects on circulating biomarkers associated with cardiovascular risk, safety and tolerability over 12 weeks Study Listed on
LPL110118 Completed A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety - Study Listed on
LPT108741 Terminated A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects with ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer
LPT109096 Relinquished Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer
LPT109747 Relinquished An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer
LPT111110 Relinquished A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
LPT111111 Relinquished LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin bound Paclitaxel (nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer
LTG9603 Completed Use of Lamotrigine Adjunctive Therapy in Patients With Mental Retardation and Epilepsy: A Multicentre, Double-Blind, Placebo-Controlled Study with Evaluation of Behavioural Effects.



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.